source
- GSK launches three-year cost-cutting plan as new CEO targets R&D efficiencyGSK announced a three-year restructuring program designed to cut costs and sharpen focus on its advanced assets. The plan was presented by CEO Luke Miels, who has been in the role for just over si…
- Oak Hill Bio to go public via SPAC merger, securing $175 million for Angelman syndrome programOak Hill Bio announced it will become a publicly traded company through a merger with the special purpose acquisition company Research Alliance Corporation III. The transaction will provide $75 mi…